drugset / Trial / NCT00305019

Safety and Antiviral Activity of Clevudine in Patients Infected With Hepatitis B Virus

NCT00305019

Phase 2 Terminated 120 enrolled Bukwang Pharmaceutical
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the antiviral effects and safety of clevudine 30 mg once a day (QD) and 50 mg QD in patients infected with hepatitis B virus (HBV).

Timeline

Start
2002-07
Primary completion
Completion
2004-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Clevudine Small molecule 30 mg
Subject Clevudine Small molecule 50 mg